Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.57 |
| ▸ | IL1RN | P18510 | 3/20 | 0.57 |
| ▸ | NPY4R | P50391 | 2/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18257509 | 1.00 | ALDH1A1 (0.57) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL18171940 | 0.99 | ERAP2 (0.56) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL17894106 | 0.99 | ERAP2 (0.56) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL17894107 | 0.99 | ERAP2 (0.56) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL18171932 | 0.99 | ERAP2 (0.56) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL2633273 | 0.92 | CTSL (0.51) | ERAP2ERAP1IL1RNNPY4RNPY1R | |
| SCHEMBL18257494 | 0.91 | CAPN1 (0.56) | ERAP2ERAP1IL1RNCAPN1 | |
| SCHEMBL20825249 | 0.91 | CAPN1 (0.56) | ERAP2ERAP1IL1RNCAPN1 | |
| SCHEMBL10085194 | 0.91 | ALDH1A1 (0.57) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL29076930 | 0.90 | CAPN1 (0.55) | ERAP2ERAP1IL1RNCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159586-A1 | INHIBITORS OF HUMAN EPIDIDYMUS PROTEIN 4 | UNIVERSITY OF ROCHESTER | 2023-05-25 | — | — | US | disclosed |
| WO-2021216670-A1 | INHIBITORS OF HUMAN EPIDIDYMUS PROTEIN 4 | UNIVERSITY OF ROCHESTER (US) | 2021-10-28 | — | — | WO | disclosed |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2020-10-13 | — | — | US | disclosed |
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-01-28 | — | — | US | disclosed |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2019-09-19 | — | — | US | disclosed |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-07-30 | — | — | US | disclosed |
| US-20190085026-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Laurus Labs Ltd. (IN) | 2019-03-21 | — | — | US | disclosed |
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-08-04 | — | — | US | disclosed |
| US-8324174-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120277146-A1 | Compounds For Enzyme Inhibition | ONYX PHARMACEUTICALS INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120094928-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094926-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8129346-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7491704-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491704-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | PROTEOLIX, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232818-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544189-B2 | Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide | OPRL1, PNMT, HTR1A | ALDH1A1 703/4885THRB 1490/4885CYP2C9 257/4885 |
| US-20190085026-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PRCP, SF3B5, GBA1 | ALDH1A1 3950/4885THRB 4694/4885CYP2C9 1455/4885 |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | ALDH1A1 3880/4885THRB 4652/4885CYP2C9 1487/4885 |
| US-20160222057-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | ALDH1A1 2989/4885THRB 2838/4885CYP2C9 1451/4885 |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | ALDH1A1 3880/4885THRB 4652/4885CYP2C9 1487/4885 |
| US-20080200398-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885THRB 2511/4885CYP2C9 1013/4885 |
| US-20230159586-A1 | INHIBITORS OF HUMAN EPIDIDYMUS PROTEIN 4 | MAN2B2, NASP, BRDT | ALDH1A1 1909/4885THRB 1636/4885CYP2C9 4829/4885 |
| US-20120094928-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885THRB 2511/4885CYP2C9 1013/4885 |
| US-20120094926-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885THRB 2511/4885CYP2C9 1013/4885 |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SF3B5, PRCP, GBA1 | ALDH1A1 3880/4885THRB 4652/4885CYP2C9 1487/4885 |
| US-20120277146-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | ALDH1A1 2975/4885THRB 2511/4885CYP2C9 1013/4885 |
| US-20070191284-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, PSMB1 | ALDH1A1 3506/4885THRB 3211/4885CYP2C9 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.